CymaBay Therapeutics - Stock Split History | CBAY

Stock split history for CymaBay Therapeutics since 2019. Prices shown are actual historical values and are not adjusted for either splits or dividends. Please see the "Historical Prices" tab for adjusted price values.
CymaBay Therapeutics Annual Stock Splits
CymaBay Therapeutics Quarterly Stock Splits
Sector Industry Market Cap Revenue
Medical Medical - Generic Drugs $0.375B $0.010B
CymaBay Therapeutics Inc. is a biopharmaceutical company. It is focused on the development and commercialization of proprietary new medicines for important human diseases. The Company's lead product candidate, arhalofenate, is being developed for the treatment of gout. CymaBay Therapeutics Inc. is based in Newark, California.
Stock Name Country Market Cap PE Ratio
Allergan (AGN) Ireland $60.567B 11.04
Teva Pharmaceutical Industries (TEVA) Israel $11.292B 4.60
Bausch Health Cos (BHC) Canada $9.994B 6.60
Mylan (MYL) United States $8.893B 3.99
Dr Reddy's Laboratories (RDY) India $6.350B 16.66
ASPEN PHARMACR (APNHY) South Africa $3.625B 0.00
Supernus Pharmaceuticals (SUPN) United States $1.156B 11.19
Amphastar Pharmaceuticals (AMPH) United States $0.825B 42.87
Homology Medicines (FIXX) United States $0.602B 0.00
Akorn (AKRX) United States $0.491B 0.00
Progenics Pharmaceuticals (PGNX) United States $0.491B 0.00
Voyager Therapeutics (VYGR) United States $0.475B 0.00
Assembly Biosciences (ASMB) United States $0.344B 0.00
Mallinckrodt Public Limited Company (MNK) United Kingdom $0.236B 0.32
Adamas Pharmaceuticals (ADMS) United States $0.154B 0.00
Sol-Gel Technologies (SLGL) Israel $0.151B 0.00
Zynerba Pharmaceuticals (ZYNE) United States $0.143B 0.00
Teligent (TLGT) United States $0.034B 0.00
China Pharma Holdings (CPHI) China $0.011B 0.00